_______________________________

The NuroPro Blood Test is Power3’s (PWRM.OB) diagnostic tool for the early detection of Neurodegenerative diseases. The analysis is designed as a tool for physicians to diagnose various degenerative diseases of the brain and nervous system. The test involves monitoring the concentration of 59 proteins in blood serum to accurately detect and distinguish between Alzheimer’s disease, ALS (Lou Gehrig’s disease), and Parkinson’s disease. The samples showed that the changes in the blood serum concentration of the protein biomarkers were consistent with previous Power3 results obtained in the US from Parkinson’s disease patients. Power3 has validated its method for collection, storage, shipping, processing, and biostatistical analysis protocols.

About Power3 Medical

Power3 Medical (PWRM.OB) is a leader in neurodegenerative disease, and cancer biomarkers. Diagnostic tests reported that Its President and CSO, Dr. Ira Goldknopf at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, described the company’s unique ability to employ PWRM’s blood protein biomarkers to differentially diagnose mild Alzheimer’s and Parkinson’s diseases distinguish between them, distinguish from normal controls, and distinguish from patients with Alzheimer’s and Parkinson’s like disorders (disease controls) and distinguish drug naïve and drug treated patients. Power3 Medical is also, a leading edge biotechnology company engaged in the early detection, monitoring, and targeting of diseases through the analysis of proteins. Visit power3 medical(PWRM.OB) at http://www.power3medical.com/com for more information.

________________________

PLEASE BE SURE TO VISIT CRWESELECT.NING.COM

***************************ADVERTISEMENTS**************************

Disclaimer: Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment (read more) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).

The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.